ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1039

Racial/Ethnic Differences in Socioeconomic Status (SES) and Health-Related Quality of Life (HRQL) Among Adults with Glomerular Disease in Cure Glomerulonephropathy (CureGN)

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Krissberg, Jill, Stanford Health Care, Redwood City, California, United States
  • Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Almaani, Salem, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Foroncewicz, Bartosz, Medical University of Warsaw, Warsaw, Poland
  • Hidalgo, Guillermo, Eastern Carolina University, Greenville, North Carolina, United States
  • Hingorani, Sangeeta R., Seattle Children’s Hospital, Seattle, Washington, United States
  • Hladunewich, Michelle A., University of Toronto, Toronto, Ontario, Canada
  • Jain, Koyal, University of North Carolina Kidney Center, Chapel Hill, North Carolina, United States
  • Kopp, Jeffrey B., NIDDK, NIH, Bethesda, Maryland, United States
  • Lafayette, Richard A., Stanford University, Stanford, California, United States
  • Moszczuk, Barbara, Medical University of Warsaw, Warsaw, Poland
  • Mucha, Krzysztof, Medical University of Warsaw, Warsaw, Poland
  • Nestor, Jordan Gabriela, Columbia University, New York, New York, United States
  • Parekh, Rulan S., The Hospital For Sick Children, Toronto, Ontario, Canada
  • Tuttle, Katherine R., University of Washington School of Medicine, Spokane, Washington, United States
  • Vasylyeva, Tetyana L., Texas Tech Health Sciences Center, Lubbock, Texas, United States
  • O'Shaughnessy, Michelle M., Stanford University, Stanford, California, United States

Adults with glomerular disease have poor HRQL. However, the effect of race/ethnicity and SES on HRQL in this population remains largely unknown.


CureGN is a 70-center cohort study of patients with MCD, FSGS, MN, or IgAN/IgAV. We compared adult patient characteristics (demographics, disease duration/severity, medications, SES) across racial/ethnic groups. Multivariable logistic and linear regression models, created using best subsets and backwards selection, were used to examine associations between race/ethnicity and HRQL, as measured by missed school due to kidney disease and baseline PROMIS questionnaire items.


Among 854 White, 220 Black, and 120 Hispanic adults, Blacks were most likely to have FSGS and had the highest urine protein, lowest serum albumin, and most severe edema. Hispanics were most likely to have IgAN/IgAV and had the lowest eGFR. Compared to Whites, Blacks or Hispanics were less likely to have completed college (48, 27, and 29%, p<0.001) or to have private insurance (76, 65, and 50%, p<0.001), and were more likely to be on medical/disability leave or unemployed (11, 23, and 24%, p<0.001). No racial/ethnic differences in missed work/school were observed. Blacks (but not Hispanics) had significantly worse global physical health, global mental health, and fatigue (table). However, after adjusting for SES and other factors, these differences in HRQL largely disappeared.


Among CureGN participants, Black or Hispanic (vs. White) participants were less likely to have completed college, to have private insurance, or to be employed. However, minority race/ethnicity was not independently associated with HRQL as measured in this study.


  • NIDDK Support